Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HSV-1 reactivation as an emergent property of neuronal stress: implications for traumatic brain injury.

Journal of neuroinflammation·2026
Same author

Nanoscale elemental mapping reveals the effect of light and temperature on Gephyrocapsa huxleyi coccoliths.

Journal of phycology·2026
Same author

Dogcatcher2: Improved statistical detection of transcriptional readthrough and repetitive element analysis across sequencing platforms.

bioRxiv : the preprint server for biology·2026
Same author

Stable isotope analysis of western Lake Superior predatory fishes, part two: prey source contributions.

Journal of Great Lakes research·2026
Same author

Restoring RCAN1 dosage mitigates sleep and EEG abnormalities in a Down syndrome model.

Neurobiology of disease·2026
Same author

Insight into the Advancement of Synthesis and Biological Activity of Pyridine and Its Derivatives: A Review.

Mini reviews in medicinal chemistry·2026
Same journal

Coordinated Subpocket Engagement Underlies Nitazene Potency at the μ-Opioid Receptor.

ACS chemical neuroscience·2026
Same journal

Quantitative Assessment of Neurometabolism by Deuterium and Proton NMR Spectroscopy Using [6,6'-<sup>2</sup>H<sub>2</sub>]Glucose.

ACS chemical neuroscience·2026
Same journal

NLX-112, a Selective 5-HT<sub>1A</sub> Receptor Agonist, Upregulates GDNF and is Neuroprotective Against MPTP-Induced Nigrostriatal Degeneration in a Mouse Model of Parkinson's Disease.

ACS chemical neuroscience·2026
Same journal

Bithiophene Scaffold for PET Imaging and Photosensitization as a Novel Theranostic Platform Targeting Amyloid-β Aggregates.

ACS chemical neuroscience·2026
Same journal

Low Agonism and Balanced Pathway Modulation Distinguish an M1 Muscarinic Receptor Positive Allosteric Modulator Lacking Cholinergic Adverse Effects.

ACS chemical neuroscience·2026
Same journal

Imaging Synaptic Vesicle Protein SV2C with <sup>18</sup>F-UCB-F: An In Vitro Autoradiography and In Vivo NHP PET Study.

ACS chemical neuroscience·2026
See all related articles

Related Experiment Video

Updated: Aug 20, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K

Identifying an Optimal Neuroinflammation Treatment Using a Nanoligomer Discovery Engine.

Sadhana Sharma1, Curtis Borski2,3, Jessica Hanson2,3

  • 1Sachi Bioworks, Colorado Technology Center, 685 S Arthur AvenueLouisville, Colorado 80027, United States.

ACS Chemical Neuroscience
|November 21, 2022
PubMed
Summary
This summary is machine-generated.

Chronic neuroinflammation damages the brain and is linked to neurodegenerative diseases. Researchers developed a novel Nanoligomer therapy, delivered via simple injection, that effectively reverses neuroinflammation in mice, offering hope for new treatments.

Keywords:
Chronic neuroinflammationLPS-induced neuroinflammationdrug discoverygene therapyneurodegenerationsleep countermeasuretarget validation

More Related Videos

Focused Ion Beam Lithography to Etch Nano-architectures into Microelectrodes
13:49

Focused Ion Beam Lithography to Etch Nano-architectures into Microelectrodes

Published on: January 19, 2020

6.8K
Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity
08:37

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity

Published on: October 25, 2016

7.0K

Related Experiment Videos

Last Updated: Aug 20, 2025

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.5K
Focused Ion Beam Lithography to Etch Nano-architectures into Microelectrodes
13:49

Focused Ion Beam Lithography to Etch Nano-architectures into Microelectrodes

Published on: January 19, 2020

6.8K
Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity
08:37

Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity

Published on: October 25, 2016

7.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Chronic neuroinflammation, involving microglia and astrocytes, is implicated in neurodegenerative diseases like Alzheimer's, Multiple Sclerosis, and Parkinson's.
  • Current treatments for neuroinflammation face challenges due to the blood-brain barrier, necessitating invasive delivery methods.
  • Effective, non-invasive strategies are needed to target and reverse chronic neuroinflammation.

Purpose of the Study:

  • To develop a novel, non-invasive neurotherapeutic for chronic neuroinflammation using a Nanoligomer Discovery Engine.
  • To identify and validate key upstream regulators and canonical pathways for therapeutic intervention.
  • To screen and optimize sequence-specific peptide molecules for targeted gene expression modulation.

Main Methods:

  • Utilized a high-throughput drug discovery platform incorporating bioinformatics and AI for target identification and molecule design.
  • Screened downregulation of proinflammatory cytokines (IL-1β, TNF-α, IL-6), inflammasomes (NLRP1), and transcription factors (NF-κβ).
  • Validated lead Nanoligomers targeting NF-κβ and TNFR1 through in vitro cell-based assays and in vivo mouse models of LPS-induced neuroinflammation.

Main Results:

  • Identified a combination Nanoligomer therapy (SB_NI_111) targeting NF-κβ and TNFR1 as the lead candidate.
  • Demonstrated significant suppression of LPS-induced neuroinflammation in the mouse hippocampus following a single intraperitoneal injection of low-dose SB_NI_111.
  • The treatment did not require special formulation and was delivered via simple intraperitoneal injection.

Conclusions:

  • The developed Nanoligomer approach offers a promising, non-invasive strategy for treating chronic neuroinflammation.
  • The lead neurotherapeutic molecule SB_NI_111 shows potential for treating neurodegenerative diseases and other conditions linked to neuroinflammation.
  • This platform technology has broader applicability for developing reversible gene therapies targeting various neurological disorders.